News

The all-oral combination comprises Presidio’s HCV NS5A inhibitor (PPI-668), Boehringer’s HCV protease inhibitor Faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. The trial

Ascending doses of N6022 will be evaluated in the multi center, double-blind study that is being conducted in collaboration with the Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN).

The Kids VitaRocks product line features antioxidants, vitamins A, B, C, D and E, as well as calcium, iodine, magnesium, zinc and selenium. Designed for children of age

The pharma company had also received £1m from the government agency for the development of novel meningococcal B vaccine, MenBioVax in late 2012. ImmBio’s vaccine candidates are based

The lymphatic mapping procedure identifies and biopsies lymph nodes that may contain tumor metastases and determine if cancer has spread beyond the primary tumor. Lymphoseek is a receptor

Under the agreement, Focus Diagnostics will gain the global rights to integrate HyBeacons PCR probe technology into its molecular diagnostic products and services. HyBeacons probes are sequence specific

LIPO-202 is an injectable pharmaceutical designed to produce aesthetic reduction of subcutaneous abdominal fat. Lithera president and CEO George Mahaffey said, "Following our recent Series C financing, Lithera

As per the agreement, Receptos will lead a Phase 2 clinical study to demonstrate proof-of-concept in Eosinophilic Esophagitis (EoE), an indication designated as an Orphan Disease by the

The company has developed NT0202, leveraging its extended-release technology, as a treatment to attention deficit hyperactivity disorder (ADHD) and is requesting for manufacturing and marketing approval of the